Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

IRLAB Therapeutics

MCap

SEK653m

Last close

SEK14.10

▲ 1.50 (11.90%)

VolitionRx

MCap

USD51m

Last close

USD0.60

▲ 0.05 (9.82%)

Portobello SpA

MCap

EUR12m

Last close

EUR2.38

▲ 0.20 (9.17%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Cantargia – executive interview

Cantargia – executive interview

Cantargia — 8 videos in collection

More on this equity

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme, the most advanced being a Phase IIa CANFOUR trial for pancreatic cancer and non-small cell lung cancer. CAN10 is being developed for systemic sclerosis and myocarditis, with clinical development expected to start in early 2022.

In this video, the company’s chief executive officer Göran Forsberg provides an update on R&D progress, including a summary of the promising results Cantargia recently reported from the pancreatic cancer arm of the CANFOUR trial.

< Previous

Next >

You may also be interested in these:

Healthcare

24.06.22

Cantargia - executive interview

Healthcare

16.03.22

Cantargia – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free